RVNC News and Press, Revance Therapeutics Inc. From 04/08/19

– Unprecedented clinical results for DaxibotulinumtoxinA for Injection (DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17 th Aesthetics & Anti-Aging Medical World Congress in Monte-Carlo – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biote...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...

Allergan ( AGN ) originally received FDA approval for Botox type A in 2002, derived from botulinum toxin, made by the bacteria that causes botulism (clostridium botulinum). Many are familiar with the cosmetic uses of Botox (onabotulinum toxin A), but not so many are familiar with the medical u...

Despite failures and headwinds, there are many believers in the underlying value of Allergan Allergan ( AGN ) faces numerous headwinds. The most visible headwind was Rapastinel, which recently failed to meet both primary and secondary endpoints in three pivotal studies for major depressive...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences. President and Chief Executive Of...

Revance Therapeutics, Inc. (RVNC) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Daniel Browne - President and Chief Executive Officer Tobin Schilke - Chief Fin...

Revance Therapeutics (NASDAQ: RVNC ): Q4 GAAP EPS of -$1.12 misses by $0.15 . Revenue of $0.49M misses by $0.86M . Press Release More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed- -On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019- -Raised approximately $108 million net proceeds from public stock offering on January...

CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more ...